Executive Intelligence

David Brown

Founder

David Brown is listed as a founder of Healx based in United Kingdom on Brel Digital’s verified company intelligence record.

In this profile

Quick Facts

  • Role Founder
  • Company Healx
  • Country United Kingdom
  • Industry AI in Healthcare
  • Founded 2014
  • Known For Healx demonstrates how AI drug-discovery platforms transition from repurposing hypotheses to owned clinical-stage assets — its…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

David Brown appears in Brel Digital’s verified company_founders attribution for Healx based in United Kingdom in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified Healx profile): Cambridge AI biotech discovering and advancing rare-disease therapies through Healnet and a growing clinical-stage portfolio Why the company matters (verified company field): Healx demonstrates how AI drug-discovery platforms transition from repurposing hypotheses to owned clinical-stage assets — its 2025 Vuja De Sciences transaction added a second oncology program and shows rare-disease AI vendors becoming hybrid biotechs, not just software licensors. Official company website on file: https://healx.io. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2014 Company founded

    Healx was founded in 2014 per the company profile source on file.

    Source
  2. 2014 Development

    2014: Healx founded in Cambridge by Tim Guilliams and David Brown.

    Source
  3. 2025 Development

    September 23, 2025: Healx entered strategic transaction with Vuja De Sciences to advance HLX-4310 osteosarcoma program.

    Source
  4. 2025 Development

    2025: Healx advanced HLX-1502 neurofibromatosis type 1 program in Phase 2 trials.

    Source

Connected Company

Connected Products

Connected Reports

Connected Insights

Industry Intelligence

David Brown appears in Brel Digital’s verified company_founders attribution for Healx based in United Kingdom in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified Healx profile): Cambridge AI biotech discovering and advancing rare-disease therapies through Healnet and a growing clinical-stage portfolio

Why the company matters (verified company field): Healx demonstrates how AI drug-discovery platforms transition from repurposing hypotheses to owned clinical-stage assets — its 2025 Vuja De Sciences transaction added a second oncology program and shows rare-disease AI vendors becoming hybrid biotechs, not just software licensors.

Official company website on file: https://healx.io. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

The AI Brief

Founder and company intelligence, weekly.

Subscribe